Compare Marqeta Inc (MQ) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Marqeta Inc vs Zimmer Biomet Holdings Inc — how do they compare? Marqeta Inc trades at $15.94 (market cap $1.66B), while Zimmer Biomet Holdings Inc trades at $94.73 (market cap $18.05B). The key difference: Zimmer Biomet Holdings Inc is far larger — about 10.9× Marqeta Inc's market cap, and Zimmer Biomet Holdings Inc pays a 1.01% dividend while Marqeta Inc pays none. Which is the better fit depends on your goals.
| MQ | ZBH | |
|---|---|---|
Market Cap | $1.66B | $18.05B |
Sector | Technology | Health |
52-Week High | $23.88 | $104.26 |
52-Week Low | $15.04 | $79.58 |
Enterprise Value | $970.76M | $25.11B |
Dividend Yield | — | 1.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Marqeta (MQ) trades at $16.26, down 1.93% on the day, with a bearish technical signal from moving averages. The company shows improving fundamentals with three consecutive quarterly earnings beats and positive net cash flow of $86.42M in 2025. Recent developments include expansion of Google Wallet partnership and stablecoin card initiatives. Valuation metrics remain elevated with P/E of 180.89 and EV/EBITDA of 48.53 despite modest profitability margins.
MQ offers 26% upside to consensus price target of $19.00, supported by earnings estimate revisions and strategic partnerships. Key risks include high valuation multiples, competitive payment processing landscape, and the need to sustain recent profitability improvements. Institutional sentiment leans cautious with 59% hold ratings despite recent business momentum.
ZBH trades at $94.22, down 3.93% on the day, with a bearish technical signal but oversold RSI readings. Recent earnings beats and raised 2026 guidance support fundamentals, with revenue growth and strong gross margins. Leadership promotions aim to accelerate commercial transformation, while cash flow trends show operational strength.
The stock offers upside to the $104.88 consensus target, but faces headwinds from debt levels and competitive pressures. Near-term support at $92 is critical; a hold rating aligns with mixed analyst views. Earnings execution and procedure demand growth are key catalysts for valuation expansion.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Marqeta Inc
Headquartered in Oakland, California, and founded in 2010, Marqeta provides its clients with a card-issuing platform that offers the infrastructure and tools necessary to offer digital, physical, and tokenized payment options without the need for a traditional bank. The company's open APIs are designed to allow third parties like DoorDash, Klarna, and Block to rapidly develop and deploy innovative card-based products and payment services without the need to develop the underlying technology. The company generates revenue primarily through processing and ATM fees for cards issued on its platform.
Read more on MQ →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
